
Capital Markets
SEC Compliance
Mergers & Acquisitions
Restructurings
Sophia Hudson, P.C., is a distinguished partner at Kirkland & Ellis LLP, based in New York. She leads the firm's global Capital Markets Practice Group, providing expert counsel on a wide range of capital markets transactions, including IPOs, equity offerings, and debt placements. Sophia is renowned for her commercial acumen and technical proficiency, advising both public companies and private equity sponsors. Her practice areas include Capital Markets, SEC Compliance, and Mergers & Acquisitions. Sophia's client roster features prominent names such as Bain Capital, Bristol Myers Squibb, and United Airlines. She holds a JD from the University of Michigan Law School and an AB in History from Princeton University.


- Kirkland & Ellis advised Amicus Therapeutics (Nasdaq: FOLD) on its agreed all-cash sale to BioMarin (Nasdaq: BMRN) at $14.50 per share, valuing Amicus at about $4.8bn. - The deal was unanimously approved by both boards, with Amicus’ board recommending stockholders vote in favour; expected to close in Q2 2026, subject to regulatory and Amicus stockholder approvals and other customary conditions. - The acquisition adds Galafold (Fabry) and Pombiliti + Opfolda (Pompe) to BioMarin’s lysosomal storage disorder portfolio, and includes Amicus’ U.S. rights to DMX-200 (Phase 3) for FSGS.
Dec 19 2025
5B
M&A

Partner
2018 – Unknown
Partner
2016 – 2018

- Bristol Myers Squibb entered into a financing in Europe on a date not available. - Deal value was 4700000000 Sector: Pharmaceuticals; Location: Europe. - On the acquirer side, counsel was not available, led by Sophia Hudson, Asher Qazi, Parker Davis, Lune Klappe-Regan, Richard Hong, Saud Alshaikh, Basit Khan Bangash, Sara Zablotney, Vivek Ratnam, Yewande Ford, Margot Solmssen, Phil Giglio.
Nov 21 2025
5B
Finance
1 min
AB in History, Princeton University
2000